Gluvan Tablet: Each tablet contains Vildagliptin INN 50 mg.
Not Found
Gluvan is indicated for the treatment of type 2 diabetes mellitus:
Can be administered with or without food.
Vildagliptin has a low potential for drug interactions. Vildagliptin is not a cytochrome P450 enzyme substrate and it does not inhibit or induce cytochrome P450 enzymes. So it is not likely to interact with co-medications that are substrates, inhibitors or inducers of these enzymes. No clinically relevant interactions with other oral antidiabetics (Glibenclamide, Pioglitazone, Metformin), Amlodipine, Digoxin, Ramipril, Simvastatin, Valsartan or Warfarin were observed after co-administration with Vildagliptin.
Contraindicated in patients with known hypersensitivity to Vildagliptin or any of the excipients.
The most common side effects are nausea, peripheral edema, headache, tremor, asthenia and dizziness.
Use in pregnancy: Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Vildagliptin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether Vildagliptin is excreted in human milk. It should not be administered to a nursing mother.
Use in children: Safety and effectiveness in children have not been established.
•Vildagliptin is not a substitute for Insulin in Insulin-requiring patients.
•Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
•Liver function should be monitored before treatment and every 3 months for first year and periodically thereafter.
•Should be used with caution in patients with heart failure.
Store below 30 C, keep in dry place & protect from light. Keep out of the reach of children.